Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.

ABSTRACT:

Background

Our objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving dabrafenib and trametinib.

Methods

We performed a retrospective cohort study examining the kidney outcomes of patients in a large healthcare system who received dabrafenib/trametinib between 2010 and 2019. The primary outcome was AKI, defined as a 1.5-fold increase in serum creatinine from baseline within a 12-month study period. AKI severity and etiology was determined for each case by chart review. Logistic regression was used to evaluate baseline predictors of AKI.

Results

A total of 199 patients who received dabrafenib in our healthcare system from 2010 to 2019 were included in the analysis. Forty-two patients (21%) expe

SUBMITTER: Seethapathy H 

PROVIDER: S-EPMC8875461 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature